Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allo...
M. Maulhardt, A. Angleitner, J. Büntzel et al.· Frontiers in Oncology· 0 citations
Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients, while enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
E. Shumilov, Lina J. Kolloch, Philipp Faustmann et al.· Blood Advances· 0 citations
In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.
M. Maulhardt, Lina J. Kolloch, G. Westhofen et al.· Clinical Lymphoma, Myeloma &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.